These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC. Palazzi L; Fongaro B; Leri M; Acquasaliente L; Stefani M; Bucciantini M; Polverino de Laureto P Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199427 [TBL] [Abstract][Full Text] [Related]
5. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. Coskuner-Weber O; Uversky VN Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151 [TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Devine MJ; Ryten M; Vodicka P; Thomson AJ; Burdon T; Houlden H; Cavaleri F; Nagano M; Drummond NJ; Taanman JW; Schapira AH; Gwinn K; Hardy J; Lewis PA; Kunath T Nat Commun; 2011 Aug; 2():440. PubMed ID: 21863007 [TBL] [Abstract][Full Text] [Related]
7. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice. Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553 [TBL] [Abstract][Full Text] [Related]
8. Effects of alpha-synuclein post-translational modifications on metal binding. González N; Arcos-López T; König A; Quintanar L; Menacho Márquez M; Outeiro TF; Fernández CO J Neurochem; 2019 Sep; 150(5):507-521. PubMed ID: 31099098 [TBL] [Abstract][Full Text] [Related]
9. A glimpse into the structural properties of α-synuclein oligomers. Santos J; Pallarès I; Ventura S Biofactors; 2024; 50(3):439-449. PubMed ID: 38063360 [TBL] [Abstract][Full Text] [Related]
10. Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer. Musgrove RE; Helwig M; Bae EJ; Aboutalebi H; Lee SJ; Ulusoy A; Di Monte DA J Clin Invest; 2019 Jun; 129(9):3738-3753. PubMed ID: 31194700 [TBL] [Abstract][Full Text] [Related]
11. Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. Forloni G; Artuso V; La Vitola P; Balducci C Mov Disord; 2016 Jun; 31(6):771-81. PubMed ID: 27030592 [TBL] [Abstract][Full Text] [Related]
12. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Rockenstein E; Nuber S; Overk CR; Ubhi K; Mante M; Patrick C; Adame A; Trejo-Morales M; Gerez J; Picotti P; Jensen PH; Campioni S; Riek R; Winkler J; Gage FH; Winner B; Masliah E Brain; 2014 May; 137(Pt 5):1496-513. PubMed ID: 24662516 [TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Olanow CW; Brundin P Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095 [TBL] [Abstract][Full Text] [Related]